Divi’s Labs Q3 FY26 Results: Hyderabad-headquartered Divi’s Laboratories on Wednesday reported a consolidated net profit of Rs 583 crore for the October-December period, a decline of 1.0 per cent from its net profit for the corresponding period a year ago.
The drug maker’s third-quarter revenue increased 12.3 per cent to Rs 2,604 crore, according to a regulatory filing.
Both net profit and revenue lines fell short of analyst estimates.
According to Zee Business research, Divi’s Labs was estimated to register a consolidated net profit of Rs 639 crore with Rs 2,676 crore in revenue for the quarter ended December 31.
Divi’s Labs shares receded from their intraday high moments after the earnings announcement but managed to stay in green territory.
Divi’s Labs shares
At 12:45 pm, the stock was up 0.9 per cent at Rs 6,228.8 apiece on BSE.
Earlier on Wednesday, the largecap pharma stock had risen as much as 2.3 per cent to Rs 6,313.8 apiece, gaining for a third straight session.
At these levels, the stock is down 1.5 per cent for the year, largely in line with dips of 0.8 per cent and 1.2 per cent in the Nifty50 and Nifty Pharma indices, respectively.
In the last one year, Divi’s shares have gained 4.9 per cent, while the headline and pharma gauges have risen 12.4 per cent and 5.3 per cent, respectively.
Doonited Affiliated: Syndicate News Hunt
This report has been published as part of an auto-generated syndicated wire feed. Except for the headline, the content has not been modified or edited by Doonited
